MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • MDS Virtual Congress 2020

    High levodopa plasma concentration in the acute levodopa challenge test predicts levodopa-induced dyskinesia in Parkinson’s disease

    T. Shiraishi, N. Nishikawa, Y. Mukai, Y. Takahashi (Kodaira-shi, Tokyo, Japan)

    Objective: We aimed to investigate the correlation between levodopa pharmacokinetics and levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD). Background: In patients with PD, pulsatile dopaminergic…
  • MDS Virtual Congress 2020

    Loss of Weight Associated with Levodopa / Carbidopa Intestinal Gel

    A. Contreras, M. Carrascal, I. Bretón, F. Grandas (Madrid, Spain)

    Objective: To define the prevalence and severity of WL in patients of the Movement Disorders Unit of our center treated with LCIG and to analyze…
  • MDS Virtual Congress 2020

    Positive Correlations Between Quality of Life and Sleep Dysfunction in Advanced Parkinson’s Disease Patients Prior to and After 12 Months of Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis From the DUOGLOBE Study

    K.R Chaudhuri, J. Boyd, E. Cubo, I. Malaty, F. Pontieri, M. Simu, L. Bergmann, T. Gao, Y. Jalundhwala, P. Kukreja, J. Aldred (London, United Kingdom)

    Objective: To evaluate the relationship between sleep disturbances and quality of life (QoL) in advanced Parkinson’s disease (PD) patients both prior to and at month…
  • MDS Virtual Congress 2020

    Indication and long-term outcome of device-aided therapies in advanced Parkinson’s disease

    M. Shiraishi, F. Maki, M. Kato, Y. Morosawa, I. Takumi, K. Isahaya, N. Sasaki, Y. Hasegawa (Kawasaki, Japan)

    Objective: We aimed to demonstrate the real world differences in a single center. Background: Number of deep brain stimulation (DBS) and levodopa-carbidopa continuous infusion gel…
  • MDS Virtual Congress 2020

    Orthostatic hypotension in early onset Parkinson’s disease

    Z. Liu, D.N Su, J.H Zhou, T. Feng (Beijing, China)

    Objective: To investigate Orthostatic hypotension (OH)  feature in early onset Parkinson's disease (EOPD)  , especially delayed OH and acute OH post drug.  To explore OH…
  • MDS Virtual Congress 2020

    Motor subtype change between OFF and ON periods in patients with Parkinson’s disease

    O. Esquivel-Zapata, A. Abundes-Corona, F. Herrera-Rodriguez, O. Cardenas-Saenz, E. Escobar-Valdivia, Y. Ríos-Solís, H. Tellez-Lucero, A. Cervantes-Arriaga, M. Rodriguez-Violante (Mexico, Mexico)

    Objective: To identify if there is any difference in the motor subtype of PwPD between "off" stage and "on" stage. Background: Patients with Parkinson’s disease…
  • MDS Virtual Congress 2020

    12-month therapeutic evaluation of l-dopa carbidopa ascorbic acid solution (LCAS) in a cohort of Advanced Parkinson’s disease in a North-Indian tertiary care hospital

    K. Shukla, N. Sawal (Chandigarh, India)

    Objective: To prescribe LCAS to Parkinson’s disease(PD) patients whose symptoms were not adequately controlled on tablet l-dopa and compare the UPDRS-(I,II,III,IV) ON & OFF on…
  • MDS Virtual Congress 2020

    Sensorimotor inhibition relates to gait dysfunction in people with Parkinson’s disease

    D. Martini, G. Harker, R. Morris, J. Nutt, F. Horak (Portland, OR, USA)

    Objective: To determine how sensorimotor inhibition relates to objective measures of gait OFF and ON levodopa and how having Parkinson’s disease (PD) affects this relationship.…
  • MDS Virtual Congress 2020

    Claims Data Analysis of Parkinson’s Disease Medication Utilization

    M. Frazer, C. Blauer-Peterson, R. Sasane, S. Arcona, Y. Fang, R. Halpern (Eden Prairie, MN, USA)

    Objective: Characterize prominent medication utilization patterns among patients with Parkinson’s disease (PD). Background: Multiple classes of medications, as monotherapy or polytherapy, are prescribed to treat…
  • MDS Virtual Congress 2020

    Pill burden reduction in patients with advanced Parkinson’s disease: Comparative effectiveness of carbidopa/levodopa enteral suspension and Deep brain stimulation

    M. Soileau, F. Pagan, A. Fasano, R. Rodriguez-Cruz, M. Oh, P. Kandukuri, Y. Jalundhwala, Y. Bao, P. Kukreja, M. Siddiqui (Georgetown, TX, USA)

    Objective: To compare the real-world impact of initiating carbidopa/levodopa enteral suspension (CLES) or deep brain stimulation (DBS) on reducing pill burden (i.e. total number of…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley